HB0030
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3+ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
HB0030 (10-5-103 nM; 5 hours) potently mediates NK cell-dependent lysis of human TIGIT-expressing Jurkat cells in vitro, with greater cytotoxic activity than HB0036[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human TIGIT-expressing Jurkat cells, pre-activated human NK cells
-
Concentration:10-5-103 nM
-
Incubation Time:5 hours
-
Result:Mediated dose-dependent NK cell killing of TIGIT-expressing Jurkat cells.
Showed stronger cytotoxic activity compared to HB0036.
In Vivo
HB0030 (10 mg/kg; i.p.; twice weekly; 4 total doses) combined with anti-PD-L1 antibody 900458 significantly reduces tumor volume and weight, and increases intratumoral IFN-γ and TNF-α levels, in CT26-hPD-L1 tumor-bearing humanized BALB/c mice[1].
HB0030 (3 mg/kg; i.p.; twice weekly; 4 total doses) monotherapy significantly inhibits H22-hPD-L1 tumor growth with a 50% partial response rate, and its combination with HB0025 enhances efficacy to an 87.5% partial response rate in humanized BALB/c mice[1].
HB0030 (3 mg/kg; i.p.; twice weekly; 4 total doses) combined with HB0025 significantly enhances tumor inhibition compared to monotherapies in hPD-L1-expressing MC38 tumor-bearing humanized C57BL/6 mice[1].
HB0030 (10 mg/kg; i.p.; twice weekly; 4 total doses) combined with HB0025 significantly enhances tumor inhibition compared to monotherapies in hPD-L1-expressing EMT6 tumor-bearing humanized BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:hTIGIT/hPD-L1/hPD-1 humanized C57BL/6 (subcutaneously inoculated with 1×106 wild-type hPD-L1- MC38 cells on left flank and 1×106 hPD-L1+ MC38 cells on right flank, grown to ~200 mm3 over 13 days)[1]
-
Dosage:500 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced the proportion of FoxP3+ regulatory T cells (Tregs) in tumor-infiltrating lymphocytes within hPD-L1+ MC38 tumors.
No significant Treg reduction was observed in hPD-L1- MC38 tumors.
-
Animal Model:hPD-1/hPD-L1/hTIGIT humanized BALB/c (subcutaneously inoculated with 1×106 CT26-hPD-L1 cells, grown to average volume of 160 mm3)[1]
-
Dosage:10 mg/kg (in combination with 10 mg/kg anti-PD-L1 antibody 900458)
-
Administration:i.p.; twice weekly; 4 total doses
-
Result:Significantly reduced tumor volume and tumor weight compared to control.
Elevated intratumoral IFN-γ and TNF-α levels compared to control, though lower than levels in the HB0036 monotherapy group.
-
Animal Model:hPD-1/hPD-L1/hTIGIT humanized BALB/c (subcutaneously inoculated with 1×106 H22-hPD-L1 cells, grown to average volume of 100 mm3)[1]
-
Dosage:3 mg/kg (monotherapy; in combination with 2 mg/kg anti-PD-L1/VEGF bispecific antibody HB0025)
-
Administration:i.p.; twice weekly; 4 total doses
-
Result:Showed significant tumor inhibition compared to isotype control, with a partial response rate of 3/6.
Combination with HB0025 showed superior tumor suppression compared to either monotherapy, with a partial response rate of 7/8.
Gene ID
Accession
Target
TIGIT
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)